FDA Panel Tables Recommendation On O-15 Imaging Agent, Okays F-18, N-13
This article was originally published in The Gray Sheet
Executive Summary
Additional information is needed to support FDA approval of water O-15 injection as an imaging agent to measure cerebral blood flow in patients with cerebral vascular disorders, FDA's Medical Imaging Drugs Advisory Committee concluded June 29.
You may also be interested in...
CGMPs For PET Drugs Should Be Performance-Based, Not Prescriptive - ICP
Current good manufacturing practices enforced by FDA for manufacturers of positron emission tomography (PET) radiopharmaceuticals should be performance-based rather than prescriptive, representatives of the Institute for Clinical PET maintain.
CGMPs For PET Drugs Should Be Performance-Based, Not Prescriptive - ICP
Current good manufacturing practices enforced by FDA for manufacturers of positron emission tomography (PET) radiopharmaceuticals should be performance-based rather than prescriptive, representatives of the Institute for Clinical PET maintain.
PET Community And FDA Move Forward In Inspection, Drug Application Talks
Final regulations governing the manufacture of radiopharmaceutical chemicals for use with positron emission tomography will not be in place by the November 1999 deadline mandated by the FDA Modernization Act, according to officials from FDA's Center for Drug Evaluation and Research.